Announcement of Requirements and Registration for: “Data Rx: Prescription Drug Abuse Infographic Challenge”, 28860-28862 [2013-11688]
Download as PDF
tkelley on DSK3SPTVN1PROD with NOTICES
28860
Federal Register / Vol. 78, No. 95 / Thursday, May 16, 2013 / Notices
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Initial Review Group; Diabetes,
Endocrinology and Metabolic Diseases B
Subcommittee.
Date: June 12–13, 2013.
Open: June 12, 2013, 8:30 a.m. to 9:00 a.m.
Agenda: To review policy and procedures.
Place: Sir Francis Drake Hotel, 450 Powell
Street at Sutter, San Francisco, CA 94102.
Closed: June 12, 2013, 9:00 a.m. to 5:00
p.m.
Agenda: To review and evaluate grant
applications.
Place: Sir Francis Drake Hotel, 450 Powell
Street at Sutter, San Francisco, CA 94102.
Closed: June 13, 2013, 8:30 a.m. to 5:00
p.m.
Agenda: To review and evaluate grant
applications.
Place: Sir Francis Drake Hotel, 450 Powell
Street at Sutter, San Francisco, CA 94102.
Contact Person: John F. Connaughton,
Ph.D., Chief, Chartered Committees Section,
Review Branch, DEA, NIDDK, National
Institutes of Health, Room 753, 6707
Democracy Boulevard, Bethesda, MD 20892–
5452, (301) 594–7797,
connaughtonj@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Initial Review Group; Kidney, Urologic and
Hematologic Diseases D Subcommittee.
Date: June 19–20, 2013.
Open: June 19, 2013, 8:00 a.m. to 8:30 a.m.
Agenda: To review policy and procedures.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Closed: June 19, 2013, 8:30 a.m. to 5:00
p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Closed: June 20, 2013, 8:00 a.m. to 12:00
p.m.
Agenda:To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Barbara A. Woynarowska,
Ph.D., Scientific Review Administrator,
Review Branch, DEA, NIDDK, National
Institutes Of Health, Room 754, 6707
Democracy Boulevard, Bethesda, MD 20892–
5452, (301) 402–7172,
woynarowskab@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Initial Review Group; Digestive Diseases and
Nutrition C Subcommittee.
Date: June 26–27, 2013.
Open: June 26, 2013, 6:30 p.m. to 7:00 p.m.
Agenda: To review policy and procedures.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Closed: June 26, 2013, 7:00 p.m. to 10:00
p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Closed: June 27, 2013, 8:30 a.m. to 5:00
p.m.
VerDate Mar<15>2010
18:13 May 15, 2013
Jkt 229001
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Robert Wellner, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 706, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, rw175w@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: May 10, 2013.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–11599 Filed 5–15–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Announcement of Requirements and
Registration for: ‘‘Data Rx:
Prescription Drug Abuse Infographic
Challenge’’
Authority: 15 U.S.C. 3719.
The ‘‘Data Rx: Prescription
Drug Abuse Infographic Challenge
Concept’’ challenges the general public
to create an infographic that presents
information, rooted in the current
research, concerning the growing trend
of prescription drug abuse. The
infographic should be designed to
inform and educate the general public
in interesting, novel, and creative ways
about the dangers involved with the
abuse of prescription drugs.
DATES: (1) Submission Period begins
May 13, 2013, 12:01 a.m., EDT.
(2) Submission Period ends June 14,
2013, 11:59 p.m., EDT.
(3) Judging will take place between
June 11–July 15, 2013.
(4) Winners will be notified and
prizes awarded July 30, 2013.
FOR FURTHER INFORMATION CONTACT: Dr.
Bethany Deeds, Deputy Branch Chief,
Epidemiology Research Branch,
Division of Epidemiology, Services and
Prevention Research, National Institute
on Drug Abuse, Phone: 301–402–1935,
email deedsb@nida.nih.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Subject of Challenge Competition
Prescription drug abuse is a growing
drug problem for America. Rates of
death by drug overdose have more than
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
tripled since 1990. Most of these deaths
are caused by prescription drugs.
Infographics are frequently used to
communicate complex information in a
clear, concise and visually appealing
manner to the public. Compared to
other topical areas (e.g., politics,
economics) the usage of infographics in
health science is extremely limited, and
infographics relevant to substance use
and abuse rarely utilize primary data
sources.
The infographic submissions in
response to ‘‘Data Rx: Prescription Drug
Abuse Infographic Challenge Concept’’
(the ‘‘Challenge’’) are intended to
increase awareness about the dangers of
prescription drug abuse based on latest
research.
This Challenge is in accordance with
the National Institute on Drug Abuse
(NIDA) statutory authority, described in
42 U.S.C. 285o. The general purpose of
NIDA is the conduct and support of
biomedical and behavioral research,
health services research, research
training, and health information
dissemination with respect to the
prevention of drug abuse and the
treatment of drug abusers. Consistent
with this authority, one of NIDA’s
strategic goals is to prevent the
initiation of drug use and the escalation
to addiction in those who have already
initiated use. Infographics that achieve
the goals underlying this Challenge will
utilize the latest research to identify the
characteristics and patterns of
prescription drug abuse and,
accordingly, will support this strategic
goal.
Entry Materials
Applications for this Challenge will
include the following components:
(1) An infographic (in .jpeg format
with at least a 300 dots- per-inch [dpi]
resolution) that increases awareness and
clearly outlines the associated dangers
of prescription drug abuse.
(2) A 1-page summary to accompany
the infographic (4,000-character
maximum). Develop a summary that
explains your main points, selected
approach and what conclusions the data
visualization helps make. References are
required and do not count towards the
character limit.
(3) Written consent to the eligibility
rules upon or before submitting an
application.
All Entry Materials must be in
English. All requested information must
be provided for your application to be
valid.
All Entry Materials, including items 1
through 3, must be submitted to
Challenge.gov which is an online
challenge platform administered by the
E:\FR\FM\16MYN1.SGM
16MYN1
Federal Register / Vol. 78, No. 95 / Thursday, May 16, 2013 / Notices
tkelley on DSK3SPTVN1PROD with NOTICES
U.S. General Services Administration
(GSA) that empowers the U.S.
Government and the public to bring the
best ideas and top talent to bear on our
nation’s most pressing challenges.
Access the www.challenge.gov Web site
and search for ‘‘Data Rx: Prescription
Drug Abuse Infographic Challenge.’’
Rules for Participating in the Challenge
Competition
To be eligible to win a prize under
this Challenge, an individual or entity:
(1) Shall have registered to participate
in the Challenge under the rules
promulgated by the National Institute
on Drug Abuse (NIDA);
(2) Shall have complied with all the
requirements under this section;
(3) In the case of a private entity, shall
be incorporated in and maintain a
primary place of business in the United
States, and in the case of an individual,
whether participating singly or in a
group, shall be a citizen or permanent
resident of the United States;
(4) In the case of an individual, must
be at least 18 years old at the time of
entry;
(5) May not be a Federal entity or
Federal employee acting within the
scope of their employment;
(6) Shall not be an HHS employee
working on their applications during
assigned duty hours;
(7) Shall not be an employee of the
National Institutes of Health (NIH);
however, employees of other Operating
Divisions within the Department of
Health and Human Services (HHS) (e.g.,
Centers for Disease Control and
Prevention (CDC), Substance Abuse and
Mental Services Administration
(SAMHSA)) are eligible to participate;
(8) In the case of Federal grantees,
may not use Federal funds to develop a
Challenge application unless it is
consistent with the purpose of their
grant award;
(9) In the case of Federal contractors,
may not use Federal funds from a
contract to develop a Challenge
application or to fund efforts in support
of a Challenge application.
An individual or entity shall not be
deemed ineligible because the
individual or entity used Federal
facilities or consulted with Federal
employees during the Challenge if the
facilities and employees are made
available to all individuals and entities
participating in the Challenge on an
equitable basis.
Process for Registration and Submitting
an Entry
To register for this Challenge,
participants must access the
www.challenge.gov Web site and search
VerDate Mar<15>2010
18:13 May 15, 2013
Jkt 229001
for ‘‘Data Rx: Prescription Drug Abuse
Infographic Challenge Concept.’’ A
registration link for the challenge can be
found on the landing page under this
Challenge description.
Amount of the Prize
Up to three monetary prizes will be
awarded: $3,000 for 1st place, $2,000 for
2nd place, and $1,000 for 3rd place.
First, second, and third place winners
will also have their infographic featured
on visualizing.org, the creative
community for infographic data and
design. Depending on the number of
applications, NIDA may also choose to
post and recognize additional
infographics on its Web site.
Payment of the Prize
Prizes awarded under this Challenge
will be paid by electronic funds transfer
and may be subject to Federal income
taxes. HHS will comply with the
Internal Revenue Service withholding
and reporting requirements, where
applicable.
Basis Upon Which Winner Will Be
Selected
The judging panel will make
recommendations based upon the
following three criteria:
1. Creativity and aesthetics of the
infographic. (5 points) Like artwork, an
infographic should be designed to
capture the attention of the viewer and
tell a story through creative use of
visuals and layout. How original and
attractive is the infographic?
2. Clarity in articulating the
prescription drug abuse problem. (5
points) At its core, the potential value
of data visualization lies in the ability
to synthesize and convey complex data
clearly and succinctly. How distinctly
does the product illuminate the problem
of prescription drug abuse?
3. Success in translating multiple data
sets into relevant visual information. (5
points) Synthesizing multiple, large
datasets to deliver relevant information
to the public in a visually compelling is
an important feature of an infographic.
The inclusion of more data sets does not
necessarily translate to a better
infographic if it does not effectively
convey complex information. How well
does the data visualization product
accomplish this?
The application must not use HHS’s
logo or official seal or the logo of NIDA
in the application, and must not claim
federal government endorsement.
Scores from each criterion will be
weighted equally for a maximum score
of 15. All applications will be held until
after the deadline is reached for a
simultaneous judging process.
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
28861
NIDA reserves the right to disqualify
and remove any application which is
deemed, in the judging panel’s
discretion, inappropriate, offensive,
defamatory, or demeaning.
The evaluation process will begin by
de-identifying the applications and
removing those that are not responsive
to this Challenge or not in compliance
with all rules of eligibility. Judges will
examine all applications in accordance
with the judging criteria outlined above
and meet to discuss the most
meritorious entries. Final
recommendations will be determined by
a vote.
Additional Information
Possible data sources include (but are
not limited to):
• Arrestee Drug Abuse Monitoring
Data (ADAM; https://
www.whitehouse.gov/ondcp/arresteedrug-abuse-monitoring-program)
• Behaviors Risk Factor Surveillance
Survey (BRFSS: https://www.cdc.gov/
brfss/)
• Drug Abuse Warning Network
(DAWN; https://www.samhsa.gov/data/
DAWN.aspx)
• Monitoring the Future (MTF;
https://www.monitoringthefuture.org/)
• National Epidemiologic Survey on
Alcohol and Related Conditions
(NESARC; https://www.sgim.org/
communities/research/datasetcompendium/national-epidemiologicsurvey-on-alcohol-and-relatedconditions-nesarc)
• National Health Interview Survey
(NHIS; https://www.cdc.gov/nchs/
nhis.htm)
• National Longitudinal Study of
Adolescent Health (Add Health; https://
www.cpc.unc.edu/projects/addhealth)
• National Longitudinal Surveys
(NLS; https://www.bls.gov/nls/)
• National Survey on Drug Use &
Health (NSDUH; https://
www.samhsa.gov/data/NSDUH/
2011SummNatFindDetTables/
Index.aspx)
• Treatment Episode Data Set (TEDS;
https://wwwdasis.samhsa.gov/webt/
newmapv1.htm)
• Youth Risk Behavior Surveillance
System (YRBSS; https://www.cdc.gov/
HealthyYouth/yrbs/index.htm)
• National Addiction & HIV Data
Archive Program (NAHDAP; https://
www.icpsr.umich.edu/icpsrweb/
NAHDAP/)
• Health Data Community at data.gov
(Health Data; https://
www.healthdata.gov/)
We also encourage combining or
‘‘mashing up’’ of multiple data sources.
See ‘‘Basis upon Which Winner Will Be
Selected’’ criteria 3.
E:\FR\FM\16MYN1.SGM
16MYN1
28862
Federal Register / Vol. 78, No. 95 / Thursday, May 16, 2013 / Notices
Submission Rights
Upon submission, each participant
warrants that he or she is the sole author
and owner of the work, and that the
work is wholly original and does not
infringe on any copyright or any other
rights of any third party of which the
participant is aware. Participants retain
title and full ownership in and to their
application. Participants expressly
reserve all intellectual property rights
(e.g., copyright). However, each
participant may be asked to grant to
NIDA and others acting on behalf of
NIDA, a royalty-free non-exclusive
worldwide license to use, copy for use,
and display publicly all parts of the
application for the purposes of the
Challenge. This license includes posting
or linking to the application on the
official NIDA Web site and making it
available for use by the public.
Liability
By participating in this Challenge,
participants agree to assume any and all
risks and waive claims against the
Federal Government and its related
entities, except in the case of willful
misconduct, for any injury, death,
damage, or loss of property, revenue, or
profits, whether direct, indirect, or
consequential, arising from their
participation in the Challenge, whether
the injury, death, damage, or loss arises
through negligence or otherwise.
Indemnification
By participating in this Challenge,
participants agree to indemnify the
Federal Government against third party
claims for damages arising from or
related to Challenge activities.
tkelley on DSK3SPTVN1PROD with NOTICES
Insurance
Based on the subject matter of the
contest, the type of work that it will
possibly require, as well as an analysis
of the likelihood of any claims for death,
bodily injury, or property damage, or
loss potentially resulting from Challenge
participation, participants are not
required to obtain liability insurance or
demonstrate financial responsibility in
order to participate in this Challenge.
Privacy, Data Security, Ethics, and
Compliance
Participants are required to identify
and address privacy and security issues
in their proposed projects, and describe
specific solutions for meeting them. In
addition to complying with appropriate
policies, procedures, and protections for
data that ensures all privacy
requirements and institutional policies
are met, use of data should not allow the
identification of the individual from
whom the data was collected.
VerDate Mar<15>2010
18:13 May 15, 2013
Jkt 229001
Participants are responsible for
compliance with all applicable federal,
state, local, and institutional laws,
regulations, and policy. These may
include, but are not limited to, Health
Insurance Portability and
Accountability Act (HIPAA), HHS
Protection of Human Subjects
regulations, and FDA regulations. The
following links are intended as a
starting point for addressing regulatory
requirements, but should not be
interpreted as a complete list of
resources on these issues:
HIPAA
Main link: https://www.hhs.gov/ocr/
privacy/.
Summary of the HIPAA Privacy Rule:
https://www.hhs.gov/ocr/privacy/
hipaa/understanding/summary/
index.html.
Summary of the HIPAA Privacy Rule:
https://www.hhs.gov/ocr/privacy/
hipaa/understanding/summary/
index.html.
Summary of the HIPAA Security Rule:
https://www.hhs.gov/ocr/privacy/
hipaa/understanding/
srsummary.html.
Human Subjects—HHS
Office for Human Research Protections:
https://www.hhs.gov/ohrp/.
Protection of Human Subjects
Regulations: https://www.hhs.gov/
ohrp/humansubjects/guidance/
45cfr46.html.
Policy & Guidance: https://www.hhs.gov/
ohrp/policy/.
Institutional Review Boards &
Assurances: https://www.hhs.gov/
ohrp/assurances/.
Human Subjects—U.S. Food and Drug
Administration (FDA)
Clinical Trials: https://www.fda.gov/
ScienceResearch/SpecialTopics/
RunningClinicalTrials/default.htm.
Office of Good Clinical Practice:
https://www.fda.gov/AboutFDA/
CentersOffices/
OfficeofMedicalProductsandTobacco/
OfficeofScienceand
HealthCoordination/ucm2018191.
Consumer Protection—Federal Trade
Commission (FTC)
Bureau of Consumer Protection: https://
business.ftc.gov/privacy-and-security.
Dated: May 6, 2013.
Nora Volkow,
Director, National Institute on Drug Abuse,
National Institutes of Health.
[FR Doc. 2013–11688 Filed 5–15–13; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Announcement of Requirements and
Registration for ‘‘Propose New Ideas
For Prescription Drugs Oral Overdose
Protection’’
Authority: 15 U.S.C. 3719.
Prescription drug abuse is a
growing drug problem for America. The
‘‘Propose New Ideas For Prescription
Drugs Oral Overdose Protection’’ is a
Challenge to find new and creative ways
that diminish or eliminate
overconsumption of intact opioid pills.
This notice provides information about
the requirements and registration for the
Challenge.
DATES: (1) Submission Period begins
May 13, 2013, 12:01 a.m., EDT.
(2) Submission Period ends June 14,
2013, 11:59 p.m., EDT.
(3) Judging will take place between
June 17–June 30, 2013.
(4) Winners will be notified and
prizes awarded July 8, 2013.
FOR FURTHER INFORMATION CONTACT: Dr.
Elena Koustova, Director, Office of
Translational Initiatives and Program
Innovations, Office of Director, National
Institute on Drug Abuse; NIDA
Challenge Manager; NIDA SBIR/STTR
Coordinator; Phone: 301–496–8768;
email: koustovae@nida.nih.gov;
elena.koustova@nih.gov .
SUPPLEMENTARY INFORMATION:
SUMMARY:
Subject of Challenge Competition
Prescription drugs are the secondmost abused category of drugs in the
United States, following marijuana. The
most commonly misused prescription
drugs fall into three classes:
• Opioids (pain relievers, analgesics)
which include oxycodone (OxyContin,
Roxicodone), hydrocodone (Vicodin,
Lortab), and methadone (Dolophine);
• Central nervous system (CNS)
depressants which include butalbital
(Fiorinal, Fioricet, Axocet), diazepam
(Valium), and alprazolam (Xanax);
• Stimulants which include
methylphenidate (Ritalin) and
amphetamine/dextroamphetamine
(Adderall)
Because prescription drugs are legal,
they are easily accessible, often from a
home medicine cabinet. The latest
report from the National Survey on Drug
Use and Health indicates that 70% of
people who abuse prescription pain
relievers got them from friends or
relatives. Surprisingly, the individuals
who abuse prescription drugs,
particularly teenagers, believe that these
E:\FR\FM\16MYN1.SGM
16MYN1
Agencies
[Federal Register Volume 78, Number 95 (Thursday, May 16, 2013)]
[Notices]
[Pages 28860-28862]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-11688]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Announcement of Requirements and Registration for: ``Data Rx:
Prescription Drug Abuse Infographic Challenge''
Authority: 15 U.S.C. 3719.
SUMMARY: The ``Data Rx: Prescription Drug Abuse Infographic Challenge
Concept'' challenges the general public to create an infographic that
presents information, rooted in the current research, concerning the
growing trend of prescription drug abuse. The infographic should be
designed to inform and educate the general public in interesting,
novel, and creative ways about the dangers involved with the abuse of
prescription drugs.
DATES: (1) Submission Period begins May 13, 2013, 12:01 a.m., EDT.
(2) Submission Period ends June 14, 2013, 11:59 p.m., EDT.
(3) Judging will take place between June 11-July 15, 2013.
(4) Winners will be notified and prizes awarded July 30, 2013.
FOR FURTHER INFORMATION CONTACT: Dr. Bethany Deeds, Deputy Branch
Chief, Epidemiology Research Branch, Division of Epidemiology, Services
and Prevention Research, National Institute on Drug Abuse, Phone: 301-
402-1935, email deedsb@nida.nih.gov.
SUPPLEMENTARY INFORMATION:
Subject of Challenge Competition
Prescription drug abuse is a growing drug problem for America.
Rates of death by drug overdose have more than tripled since 1990. Most
of these deaths are caused by prescription drugs. Infographics are
frequently used to communicate complex information in a clear, concise
and visually appealing manner to the public. Compared to other topical
areas (e.g., politics, economics) the usage of infographics in health
science is extremely limited, and infographics relevant to substance
use and abuse rarely utilize primary data sources.
The infographic submissions in response to ``Data Rx: Prescription
Drug Abuse Infographic Challenge Concept'' (the ``Challenge'') are
intended to increase awareness about the dangers of prescription drug
abuse based on latest research.
This Challenge is in accordance with the National Institute on Drug
Abuse (NIDA) statutory authority, described in 42 U.S.C. 285o. The
general purpose of NIDA is the conduct and support of biomedical and
behavioral research, health services research, research training, and
health information dissemination with respect to the prevention of drug
abuse and the treatment of drug abusers. Consistent with this
authority, one of NIDA's strategic goals is to prevent the initiation
of drug use and the escalation to addiction in those who have already
initiated use. Infographics that achieve the goals underlying this
Challenge will utilize the latest research to identify the
characteristics and patterns of prescription drug abuse and,
accordingly, will support this strategic goal.
Entry Materials
Applications for this Challenge will include the following
components:
(1) An infographic (in .jpeg format with at least a 300 dots- per-
inch [dpi] resolution) that increases awareness and clearly outlines
the associated dangers of prescription drug abuse.
(2) A 1-page summary to accompany the infographic (4,000-character
maximum). Develop a summary that explains your main points, selected
approach and what conclusions the data visualization helps make.
References are required and do not count towards the character limit.
(3) Written consent to the eligibility rules upon or before
submitting an application.
All Entry Materials must be in English. All requested information
must be provided for your application to be valid.
All Entry Materials, including items 1 through 3, must be submitted
to Challenge.gov which is an online challenge platform administered by
the
[[Page 28861]]
U.S. General Services Administration (GSA) that empowers the U.S.
Government and the public to bring the best ideas and top talent to
bear on our nation's most pressing challenges. Access the
www.challenge.gov Web site and search for ``Data Rx: Prescription Drug
Abuse Infographic Challenge.''
Rules for Participating in the Challenge Competition
To be eligible to win a prize under this Challenge, an individual
or entity:
(1) Shall have registered to participate in the Challenge under the
rules promulgated by the National Institute on Drug Abuse (NIDA);
(2) Shall have complied with all the requirements under this
section;
(3) In the case of a private entity, shall be incorporated in and
maintain a primary place of business in the United States, and in the
case of an individual, whether participating singly or in a group,
shall be a citizen or permanent resident of the United States;
(4) In the case of an individual, must be at least 18 years old at
the time of entry;
(5) May not be a Federal entity or Federal employee acting within
the scope of their employment;
(6) Shall not be an HHS employee working on their applications
during assigned duty hours;
(7) Shall not be an employee of the National Institutes of Health
(NIH); however, employees of other Operating Divisions within the
Department of Health and Human Services (HHS) (e.g., Centers for
Disease Control and Prevention (CDC), Substance Abuse and Mental
Services Administration (SAMHSA)) are eligible to participate;
(8) In the case of Federal grantees, may not use Federal funds to
develop a Challenge application unless it is consistent with the
purpose of their grant award;
(9) In the case of Federal contractors, may not use Federal funds
from a contract to develop a Challenge application or to fund efforts
in support of a Challenge application.
An individual or entity shall not be deemed ineligible because the
individual or entity used Federal facilities or consulted with Federal
employees during the Challenge if the facilities and employees are made
available to all individuals and entities participating in the
Challenge on an equitable basis.
Process for Registration and Submitting an Entry
To register for this Challenge, participants must access the
www.challenge.gov Web site and search for ``Data Rx: Prescription Drug
Abuse Infographic Challenge Concept.'' A registration link for the
challenge can be found on the landing page under this Challenge
description.
Amount of the Prize
Up to three monetary prizes will be awarded: $3,000 for 1st place,
$2,000 for 2nd place, and $1,000 for 3rd place. First, second, and
third place winners will also have their infographic featured on
visualizing.org, the creative community for infographic data and
design. Depending on the number of applications, NIDA may also choose
to post and recognize additional infographics on its Web site.
Payment of the Prize
Prizes awarded under this Challenge will be paid by electronic
funds transfer and may be subject to Federal income taxes. HHS will
comply with the Internal Revenue Service withholding and reporting
requirements, where applicable.
Basis Upon Which Winner Will Be Selected
The judging panel will make recommendations based upon the
following three criteria:
1. Creativity and aesthetics of the infographic. (5 points) Like
artwork, an infographic should be designed to capture the attention of
the viewer and tell a story through creative use of visuals and layout.
How original and attractive is the infographic?
2. Clarity in articulating the prescription drug abuse problem. (5
points) At its core, the potential value of data visualization lies in
the ability to synthesize and convey complex data clearly and
succinctly. How distinctly does the product illuminate the problem of
prescription drug abuse?
3. Success in translating multiple data sets into relevant visual
information. (5 points) Synthesizing multiple, large datasets to
deliver relevant information to the public in a visually compelling is
an important feature of an infographic. The inclusion of more data sets
does not necessarily translate to a better infographic if it does not
effectively convey complex information. How well does the data
visualization product accomplish this?
The application must not use HHS's logo or official seal or the
logo of NIDA in the application, and must not claim federal government
endorsement.
Scores from each criterion will be weighted equally for a maximum
score of 15. All applications will be held until after the deadline is
reached for a simultaneous judging process.
NIDA reserves the right to disqualify and remove any application
which is deemed, in the judging panel's discretion, inappropriate,
offensive, defamatory, or demeaning.
The evaluation process will begin by de-identifying the
applications and removing those that are not responsive to this
Challenge or not in compliance with all rules of eligibility. Judges
will examine all applications in accordance with the judging criteria
outlined above and meet to discuss the most meritorious entries. Final
recommendations will be determined by a vote.
Additional Information
Possible data sources include (but are not limited to):
Arrestee Drug Abuse Monitoring Data (ADAM; https://www.whitehouse.gov/ondcp/arrestee-drug-abuse-monitoring-program)
Behaviors Risk Factor Surveillance Survey (BRFSS: https://www.cdc.gov/brfss/)
Drug Abuse Warning Network (DAWN; https://www.samhsa.gov/data/DAWN.aspx)
Monitoring the Future (MTF; https://www.monitoringthefuture.org/)
National Epidemiologic Survey on Alcohol and Related
Conditions (NESARC; https://www.sgim.org/communities/research/dataset-compendium/national-epidemiologic-survey-on-alcohol-and-related-conditions-nesarc)
National Health Interview Survey (NHIS; https://www.cdc.gov/nchs/nhis.htm)
National Longitudinal Study of Adolescent Health (Add
Health; https://www.cpc.unc.edu/projects/addhealth)
National Longitudinal Surveys (NLS; https://www.bls.gov/nls/)
National Survey on Drug Use & Health (NSDUH; https://www.samhsa.gov/data/NSDUH/2011SummNatFindDetTables/Index.aspx)
Treatment Episode Data Set (TEDS; https://wwwdasis.samhsa.gov/webt/newmapv1.htm)
Youth Risk Behavior Surveillance System (YRBSS; https://www.cdc.gov/HealthyYouth/yrbs/index.htm)
National Addiction & HIV Data Archive Program (NAHDAP;
https://www.icpsr.umich.edu/icpsrweb/NAHDAP/)
Health Data Community at data.gov (Health Data; https://www.healthdata.gov/)
We also encourage combining or ``mashing up'' of multiple data
sources. See ``Basis upon Which Winner Will Be Selected'' criteria 3.
[[Page 28862]]
Submission Rights
Upon submission, each participant warrants that he or she is the
sole author and owner of the work, and that the work is wholly original
and does not infringe on any copyright or any other rights of any third
party of which the participant is aware. Participants retain title and
full ownership in and to their application. Participants expressly
reserve all intellectual property rights (e.g., copyright). However,
each participant may be asked to grant to NIDA and others acting on
behalf of NIDA, a royalty-free non-exclusive worldwide license to use,
copy for use, and display publicly all parts of the application for the
purposes of the Challenge. This license includes posting or linking to
the application on the official NIDA Web site and making it available
for use by the public.
Liability
By participating in this Challenge, participants agree to assume
any and all risks and waive claims against the Federal Government and
its related entities, except in the case of willful misconduct, for any
injury, death, damage, or loss of property, revenue, or profits,
whether direct, indirect, or consequential, arising from their
participation in the Challenge, whether the injury, death, damage, or
loss arises through negligence or otherwise.
Indemnification
By participating in this Challenge, participants agree to indemnify
the Federal Government against third party claims for damages arising
from or related to Challenge activities.
Insurance
Based on the subject matter of the contest, the type of work that
it will possibly require, as well as an analysis of the likelihood of
any claims for death, bodily injury, or property damage, or loss
potentially resulting from Challenge participation, participants are
not required to obtain liability insurance or demonstrate financial
responsibility in order to participate in this Challenge.
Privacy, Data Security, Ethics, and Compliance
Participants are required to identify and address privacy and
security issues in their proposed projects, and describe specific
solutions for meeting them. In addition to complying with appropriate
policies, procedures, and protections for data that ensures all privacy
requirements and institutional policies are met, use of data should not
allow the identification of the individual from whom the data was
collected. Participants are responsible for compliance with all
applicable federal, state, local, and institutional laws, regulations,
and policy. These may include, but are not limited to, Health Insurance
Portability and Accountability Act (HIPAA), HHS Protection of Human
Subjects regulations, and FDA regulations. The following links are
intended as a starting point for addressing regulatory requirements,
but should not be interpreted as a complete list of resources on these
issues:
HIPAA
Main link: https://www.hhs.gov/ocr/privacy/.
Summary of the HIPAA Privacy Rule: https://www.hhs.gov/ocr/privacy/hipaa/understanding/summary/.
Summary of the HIPAA Privacy Rule: https://www.hhs.gov/ocr/privacy/hipaa/understanding/summary/.
Summary of the HIPAA Security Rule: https://www.hhs.gov/ocr/privacy/hipaa/understanding/srsummary.html.
Human Subjects--HHS
Office for Human Research Protections: https://www.hhs.gov/ohrp/.
Protection of Human Subjects Regulations: https://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html.
Policy & Guidance: https://www.hhs.gov/ohrp/policy/.
Institutional Review Boards & Assurances: https://www.hhs.gov/ohrp/assurances/.
Human Subjects--U.S. Food and Drug Administration (FDA)
Clinical Trials: https://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/default.htm.
Office of Good Clinical Practice: https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/OfficeofScienceandHealthCoordination/ucm2018191.
Consumer Protection--Federal Trade Commission (FTC)
Bureau of Consumer Protection: https://business.ftc.gov/privacy-and-security.
Dated: May 6, 2013.
Nora Volkow,
Director, National Institute on Drug Abuse, National Institutes of
Health.
[FR Doc. 2013-11688 Filed 5-15-13; 8:45 am]
BILLING CODE 4140-01-P